SCHEMBL2178633

SCHEMBL2178633

O=C(Nc1ccc(-c2ccc3c(c2)CN(C(Cc2ccccc2)C(=O)O)C3=O)cc1)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 5/20 0.53
MAPT P10636 5/20 0.53
ALOX15 P16050 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
THRB P10828 3/20 0.52
MEN1 O00255 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
SDCBP O00560 2/20 0.49
SDC2 P34741 2/20 0.49
LMNA P02545 1/20 0.49
KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180556 1.00 DGAT1 (0.53) DGAT1MAPTALOX15SMN1; SMN2THRB
SCHEMBL27877713 0.94 MAPT (0.51) DGAT1MAPTALOX15SMN1; SMN2THRB
SCHEMBL2179022 0.90 DGAT1 (0.55) DGAT1MAPTSMN1; SMN2THRBMEN1
SCHEMBL2178056 0.90 DGAT1 (0.55) DGAT1MAPTSMN1; SMN2THRBMEN1
SCHEMBL2178706 0.88 DGAT1 (0.54) DGAT1MAPTSMN1; SMN2THRBMEN1
SCHEMBL2178886 0.88 DGAT1 (0.54) DGAT1MAPTSMN1; SMN2THRBMEN1
SCHEMBL2181149 0.87 DGAT1 (0.52) DGAT1MAPTALOX15SMN1; SMN2THRB
SCHEMBL2177311 0.87 DGAT1 (0.52) DGAT1MAPTALOX15SMN1; SMN2THRB
SCHEMBL2180531 0.87 DGAT1 (0.56) DGAT1MAPTSMN1; SMN2THRBMEN1
SCHEMBL2181413 0.87 DGAT1 (0.56) DGAT1MAPTSMN1; SMN2THRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885MAPT 116/4885ALOX15 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.